Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Immunotherapy and lung cytopathology: Overview and possibilities
View through CrossRef
AbstractImmunotherapy has become a promising cancer treatment in the past decade, and IHC is the most commonly used testing method for PDL‐1/PD1 evaluation. In general, PD‐L1 assays can be performed on both FFPE specimens and cytological samples. However, their use on smears is not yet well‐established or validated. Nowadays, digital images and advanced algorithms can aid in interpreting PD‐L1 in cytological samples. Understanding the immune environment of non‐small cell lung cancer (NSCLC) is critical in developing successful anticancer immunotherapies. The use of a multiplexed immunofluorescence (mIF) assay on cytological samples obtained through minimally invasive methods appears to be a viable option for investigating the immune environment of NSCLC. This review aims to briefly summarize the knowledge of the role of cytopathology in the analysis of PD‐L1 by immunocytochemistry (ICC) and future directions of cytopathology in the immunotherapy setting.
Title: Immunotherapy and lung cytopathology: Overview and possibilities
Description:
AbstractImmunotherapy has become a promising cancer treatment in the past decade, and IHC is the most commonly used testing method for PDL‐1/PD1 evaluation.
In general, PD‐L1 assays can be performed on both FFPE specimens and cytological samples.
However, their use on smears is not yet well‐established or validated.
Nowadays, digital images and advanced algorithms can aid in interpreting PD‐L1 in cytological samples.
Understanding the immune environment of non‐small cell lung cancer (NSCLC) is critical in developing successful anticancer immunotherapies.
The use of a multiplexed immunofluorescence (mIF) assay on cytological samples obtained through minimally invasive methods appears to be a viable option for investigating the immune environment of NSCLC.
This review aims to briefly summarize the knowledge of the role of cytopathology in the analysis of PD‐L1 by immunocytochemistry (ICC) and future directions of cytopathology in the immunotherapy setting.
Related Results
Lung uptake on I-131 therapy and short-term outcome in patients with lung metastasis from differentiated thyroid cancer
Lung uptake on I-131 therapy and short-term outcome in patients with lung metastasis from differentiated thyroid cancer
Abstract
Objective
It is sometimes difficult to assess I-131 lung uptake at the initial I-131 therapy because of strong artifacts from I-131 upta...
Abstract 1345: Evidence for genetic mediation of lung cancer through hay fever.
Abstract 1345: Evidence for genetic mediation of lung cancer through hay fever.
Abstract
Introduction: In the past decade, advances in genetics have led to the discovery of numerous lung cancer susceptibility variants. The majority of these vari...
Neoadjuvant Immunotherapy and Non–Small Cell Lung Cancer
Neoadjuvant Immunotherapy and Non–Small Cell Lung Cancer
Objectives:
To systematically evaluate the effectiveness and safety of neoadjuvant immunotherapy for patients with non–small cell lung cancer (NSCLC).
...
Correlation between tumor mutation burden and response to immunotherapy.
Correlation between tumor mutation burden and response to immunotherapy.
e14579 Background: The use of immunotherapy is exponentially increasing in treatment of patients with advanced solid tumors. However, the response rates vary significantly between...
Immunotherapy, Immunobiomarkers and Gene Analysis Role in the Improvement of Lung Cancer Treatment
Immunotherapy, Immunobiomarkers and Gene Analysis Role in the Improvement of Lung Cancer Treatment
Lung cancer is the second most common cancer with a poor survival rate (18.6%). Recently treatment of lung cancer has been improved starting from choosing appropriate treatment by ...
Application of PD-1/PD-L1 immune checkpoint inhibitors treating lung cancer in Yerevan Armenia: Two-center experience.
Application of PD-1/PD-L1 immune checkpoint inhibitors treating lung cancer in Yerevan Armenia: Two-center experience.
e15058 Background: Over the past few years PD-1/PD-L1 pathway blockade through immune checkpoint inhibitors appeared to be an effective treatment approach in advanced lung cancer....
Minimally Invasive Thoracoscopic Surgery of Lung Adenocarcinoma in Old Age People
Minimally Invasive Thoracoscopic Surgery of Lung Adenocarcinoma in Old Age People
Background: Lung cancer is the most frequent human malignancy and the principal cause of cancer-related death worldwide. Adenocarcinoma is now the main histologic type, accounting ...
Abstract 1657: Genome-wide association study of lung cancer: Variation in TP63 gene confers the risk of lung adenocarcinoma
Abstract 1657: Genome-wide association study of lung cancer: Variation in TP63 gene confers the risk of lung adenocarcinoma
Abstract
Lung cancer is the most common cause of death from cancer worldwide, and its incidence is increasing in East Asian and Western countries. Lung cancer compri...